Milena Dumont Milutinovic, Senior Manager of Field Applications at Quanterix, walks through the company’s ultrasensitive biomarker assay technology.
Quanterix fuels scientific discovery through ultrasensitive detection of protein biomarkers. To date, the company has delivered nearly 900 instruments to pharma and academic organisations across North America, Europe, and Asia. Its Simoa® technology has also been cited in over 2,000 peer-reviewed publications and counting.
A global company, Quanterix is headquartered outside of Boston, Mass., with support teams located across Europe. The guiding philosophy of its technology is simple: the higher the sensitivity, the greater the ability to detect proteins at their lowest levels, enabling scientists to detect disease earlier. Outlining the principles of Simoa technology and use cases, Milena Dumont Milutinovic, Senior Manager of Field Applications at Quanterix, presented at Oxford Global’s Biomarkers 2023 conference.
Related Posts
Industry Insights: Multi-omic Diagnostics
Multi-omic diagnostics are reshaping how researchers and clinicians approach complex diseases, offering deeper biological insights through the integration of multiple data types. In this interview with The Pathologist, industry experts…
Spatial Analysis
Snapshots of Health Innovation From the Edison Awards
Building the Tools Parkinson’s Disease Research Needs
A Q&A with Kishore Malyavantham, PhD, VP of R&D at Quanterix and Co-Investigator, PD-BUILD Quanterix has been named a Co-Investigator institution in PD-BUILD (Biomarker Utilization, Innovation, and Laboratory-to-Deployment), a new project…
Quanterix Named to ASAP CRN 2026 PD-BUILD Program with MJFF Support
Part of a global effort to advance Parkinson’s disease biomarkers through standardized, scalable assay development Quanterix has been selected as a Co-Investigator institution in the PD-BUILD program, part of the…
Neurology
Why biomarkers are no longer supplemental
Quanterix makes the case with ctDNA in oncology, p-tau217 in Alzheimer’s and a lab model built for longitudinal, regulatory-grade data. Biomarkers have moved from “nice-to-have” to the backbone of drug…
Neurology
Preparing The Market for Blood-Based Biomarkers
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, outlined strategies for integrating blood-based biomarkers into routine clinical care pathways, ensuring minimal disruption for patients and clinicians. Watch the full…
Neurology
Challenges of Positioning an Ultra-Sensitive Platform
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, discussed challenges in positioning Simoa in the precision health market, stressing its accuracy and reliability in diverse populations. Watch the full…
Neurology
Translating Complex Scientific Findings into Actionable Insights
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, discussed translating complex scientific findings into actionable insights for healthcare providers and stakeholders, emphasizing the importance of early disease detection. Watch…